Anti-PD-L1 antibody treatment delays melanoma tumour growth in this model but, despite PD-L1 expression in tumour cells, the anti-tumour effect of PD-L1 blockade was reduced in Batf3−/− mice which lack CD103+ DCs (Salmon et al., 2016). The gene discussed is ITGAE; the disease is melanoma.